文献速递肿瘤 PET/CT核素与放射性配体治疗

初诊未治疗前列腺癌的[18F]DCFPyL PET/CT:与ADT后PSA结局及复发相关

Initial [18F]DCFPyL PET/CT in treatment-naïve prostate cancer: correlation with post-ADT PSA outcomes and recurrence.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-04-02

前瞻性队列纳入86例接受短期ADT的前列腺癌患者,评估[18F]DCFPyL PET/CT的预后价值。原发肿瘤SUV≥6.78、原发PSMA阳性肿瘤体积PSMA-TV<41.96 cm3及转移灶PSMA-TV≥71.39 cm3与无进展生存期缩短相关;PET与临床参数对PSA50反应的预测能力有限,AUC为0.442。

要点

  • 原发肿瘤SUV≥6.78与无进展生存期缩短相关(p=0.0024)。
  • 原发PSMA-TV<41.96 cm3与无进展生存期缩短相关(p=0.038)。
  • 转移灶PSMA-TV≥71.39 cm3与无进展生存期缩短相关(p=0.012)。

核心结论

  • 治疗前原发或转移肿瘤部位的[18F]DCFPyL摄取在接受ADT的高危前列腺癌患者中具有预后相关性。
  • 作者指出需要进一步研究以在这一多层面的前列腺癌管理格局中开发稳健的预测模型。

研究设计与样本

  • 前瞻性队列研究,纳入86例接受短期ADT的前列腺癌患者。
  • 评估[18F]DCFPyL PET/CT的预后潜力,综合临床资料、基线前列腺特异性抗原(PSA)水平及影像学指标。
  • 基于PET相关参数与临床因素组合构建预测PSA水平下降(PSA50和PSA70)的模型,并采用Kaplan-Meier生存分析评估PET指标的预后价值。

主要发现

  • 原发肿瘤[18F]DCFPyL摄取升高(SUV≥6.78)与无进展生存期缩短相关(p=0.0024)。
  • 原发PSMA阳性肿瘤体积PSMA-TV<41.96 cm3与无进展生存期缩短相关(p=0.038)。
  • 转移性PSMA阳性肿瘤负荷增加(PSMA-TV≥71.39 cm3)与无进展生存期缩短相关(p=0.012)。
  • PET与临床参数对PSA50反应的预测能力有限,曲线下面积(AUC)为0.442。

关键数值与推荐

  • 原发肿瘤SUV≥6.78(p=0.0024)与无进展生存期缩短相关。
  • 原发PSMA-TV<41.96 cm3(p=0.038)与无进展生存期缩短相关。
  • 转移灶PSMA-TV≥71.39 cm3(p=0.012)与无进展生存期缩短相关。
  • PSA50预测模型AUC为0.442。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出需要进一步研究以在这一多层面的前列腺癌管理格局中开发稳健的预测模型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Positron emission tomography (PET) with prostate-specific membrane antigen (PSMA) targeting tracers has emerged as a valuable diagnostic tool for prostate cancer (PCa), androgen deprivation therapy (ADT) stands as the cornerstone treatment for advanced PCa, yet forecasting the response to hormonal therapy poses a significant clinical hurdle. METHODS: In a prospective cohort of 86 PCa patients undergoing short-term ADT, this study evaluated the prognostic potential of [18F]DCFPyL PET/CT scans. Comprehensive data encompassing clinical profiles, baseline prostate-specific antigen (PSA) levels, and imaging metrics were assessed. We developed predictive models for assessing decreases in PSA levels (PSA50 and PSA70) based on a combination of PET-related parameters and clinical factors. Kaplan-Meier survival analysis was utilized to ascertain the prognostic value of PET-based metrics. RESULTS: In this study, elevated [18F]DCFPyL uptake within the primary tumor, as indicated by a SUV ≥ 6.78 (p = 0.0024), and a reduction in the tumor volume (TV) of primary PSMA-avid tumor with PSMA-TV < 41.96 cm3 (p = 0.038), as well as an increased burden of metastatic PSMA-avid tumor, with PSMA-TV (PSMA-TV ≥ 71.39 cm3) (p = 0.012) were identified in association with diminished progression-free survival (PFS). PET and clinical parameters demonstrated constrained predictive capacity for PSA50 response as indicated by an area under the curve (AUC) of 0.442. CONCLUSION: Our study revealed that pretreatment [18F]DCFPyL uptake in primary or metastatic tumor sites is prognostically relevant in high-risk PCa patients undergoing ADT. Further research is needed to develop robust predictive models in this multifaceted landscape of PCa management.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Li Y, Wang S, Zhao S, et al. Initial [18F]DCFPyL PET/CT in treatment-naïve prostate cancer: correlation with post-ADT PSA outcomes and recurrence. Eur J Nucl Med Mol Imaging. 2024. PMID: 38563882. doi:10.1007/s00259-024-06684-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。